Skip to main content
Clinical Trials/EUCTR2012-003067-22-NL
EUCTR2012-003067-22-NLActive, not recruitingNot Applicable

Pneumonia treated with rifampicine attenuates inflammation - PRIsTINe

MC0 sitesStarted: November 19, 2012Last updated:
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
MC

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1.Patient aged 18 years or above
  • 2.Community acquired pneumonia with CURB65 score = 2
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

Exclusion Criteria

  • Known allergy to rifampicin or anaemia or thrombopenia as side effect of rifampicin in medical history
  • Medication induced hepatitis or acute liver failure
  • ????Renal failure with creatinin clearance < 25 ml/min
  • Use of voriconazol or protease inhibitors
  • health care associated pneumonia
  • Female patients who are pregnant
  • Lung transplant recipients

Investigators

Sponsor
MC

Similar Trials

Completed
Phase 4
Pneumonia treated with rifampicine attenuates inflammatio1000401810024970respiratory tract infectionpneumonia
NL-OMON39089eids Universitair Medisch Centrum40
Completed
Not Applicable
Rifampicine vermindert de ontstekingsreactie bij patienten met een (matig) ernstige longontsteking.Community Acquired PneumoniaRifampicinLipoteichoid AcidPneumolysininflammatory responsclinical outcome prognosispneumoniaEmergency medicinehospitalSpoedeisende hulpziekenhuisThuis opgelopen longontstekingCURB-65 scorerifampicinelipoteichoidzuurpneumolysineinflammatoire responsprognoseklinische uitkomstpneumonie
NL-OMON22991Prof. dr. J.T. van DisselLUMC40
Completed
Not Applicable
A clinical trial to study the effect of Rifampicin in children with bacterial meningitis
CTRI/2015/06/005951PGIMER40
Active, not recruiting
Phase 1
CLINICAL TRIAL TO EVALUATE THE EFFICIENCY OF PYRPHENIDONE FOR THE REDUCTION OF PULMONARY INFLAMMATION IN PATIENTS WITH SILICOSIS AND PROGRESSIVE MASSIVE FIBROSIS.progressive massive fibrosisMedDRA version: 20.0Level: PTClassification code 10040678Term: SilicosisSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 21.1Level: PTClassification code 10036805Term: Progressive massive fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2021-002701-94-ESFundación para la Gestión de la Investigación Biomédica de Cádiz18
Active, not recruiting
Not Applicable
Effects of rifampicin on the pharmacokinetics and pharmacodynamics of sublingual and intravenous buprenorphine
EUCTR2012-002871-32-FITurku University hospital